dronabinol has been researched along with midazolam in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (66.67) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| McMahon, LR | 2 |
| Gehrig, AK; Heinrich, T; Mikus, G; Röder, CS | 1 |
| Delatte, MS; Paronis, CA | 1 |
| Becker, GL; France, CP; Gerak, LR; Li, JX; McMahon, LR | 1 |
| Cohen, AF; de Kam, ML; Kleijn, HJ; Passier, PC; van Gerven, JM; Zuurman, L | 1 |
| Bansal, S; Paine, MF; Spindle, TR; Thummel, KE; Unadkat, JD; Vandrey, R; Weerts, EM; Zamarripa, CA | 1 |
1 review(s) available for dronabinol and midazolam
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for dronabinol and midazolam
| Article | Year |
|---|---|
Pharmacodynamic and pharmacokinetic effects of the intravenous CB1 receptor agonist Org 26828 in healthy male volunteers.
Topics: Adult; Ambulatory Surgical Procedures; Conscious Sedation; Dose-Response Relationship, Drug; Dronabinol; Humans; Hypnotics and Sedatives; Infusions, Intravenous; Injections, Intravenous; Male; Midazolam; Receptor, Cannabinoid, CB1; Young Adult | 2010 |
13 other study(ies) available for dronabinol and midazolam
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
Topics: Analgesics, Opioid; Anesthetics, Dissociative; Anesthetics, Intravenous; Anesthetics, Local; Animals; Benzoxazines; Camphanes; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cannabinoids; Cocaine; Cyclohexanols; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Female; Hallucinogens; Ketamine; Macaca mulatta; Male; Midazolam; Morphine; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2006 |
Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
Topics: Animals; Benzoxazines; Cannabinoids; Conditioning, Operant; Cyclohexanols; Discrimination Learning; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Hallucinogens; Humans; Injections, Intravenous; Injections, Subcutaneous; Ketamine; Macaca mulatta; Male; Midazolam; Morpholines; Naphthalenes; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors | 2006 |
Misleading results of screening for illicit drugs during efavirenz treatment.
Topics: Alkynes; Benzodiazepines; Benzoxazines; Cyclopropanes; Dronabinol; Drug Administration Schedule; Humans; Immunoassay; Midazolam; Reverse Transcriptase Inhibitors; Substance Abuse Detection | 2007 |
Evaluation of cannabinoid agonists using punished responding and midazolam discrimination procedures in squirrel monkeys.
Topics: Animals; Benzoxazines; Cannabinoids; Data Interpretation, Statistical; Discrimination Learning; Discrimination, Psychological; Dose-Response Relationship, Drug; Dronabinol; Food; gamma-Aminobutyric Acid; Hypnotics and Sedatives; Male; Midazolam; Morpholines; Naphthalenes; Punishment; Receptor, Cannabinoid, CB1; Saimiri | 2008 |
Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociception.
Topics: Analgesics; Analgesics, Opioid; Animals; Data Interpretation, Statistical; Discrimination, Psychological; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Female; Heroin; Hot Temperature; Hypnotics and Sedatives; Macaca mulatta; Male; Midazolam; Morphine; Morphine Dependence; Naltrexone; Narcotic Antagonists; Pain Measurement; Receptors, Opioid, mu; Substance Withdrawal Syndrome | 2008 |
Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
Topics: Adult; Caffeine; Cannabidiol; Cannabinoids; Cannabis; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dronabinol; Drug Interactions; Hallucinogens; Humans; Losartan; Midazolam; Omeprazole; Plant Extracts | 2023 |